Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.552

-1.6%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	2/13/2008 5:31:29 PM
	of 368

Sangamo BioSciences "strong buy," target price reduced 02/07/08 - JMP Securities NEW YORK, February 7 (newratings.com) - Analysts at JMP Securities reiterate their "strong buy" rating on Sangamo BioSciences Inc (SGMO). The 12-month target price has been reduced from $30 to $18. In a research note published yesterday, the analysts mention that the company has reported mixed results for 4Q, with revenues in-line with the estimates and earnings short of expectations due to higher-than-expected R&D costs. Sangamo Biosciences is expected to make several important announcements in 2008, including the results of some clinical trials and the initiation of some others, the analysts add. Sangamo Biosciences is likely to sign a big corporate collaboration agreement related to drug development later this year, JMP Securities says.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next